Literature DB >> 29863313

Time for the dawn of multimodal therapies and the dusk for mono-therapeutic trials for cholestatic liver diseases?

Martin Wagner1, Peter Fickert1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29863313     DOI： 10.1111/liv.13744

Source DB:  PubMed          Journal:  Liver Int        ISSN： 1478-3223            Impact factor:   5.828


× No keyword cloud information.
  2 in total

Review 1.  New Therapeutic Targets in Autoimmune Cholangiopathies.

Authors:  Alessio Gerussi; Martina Lucà; Laura Cristoferi; Vincenzo Ronca; Clara Mancuso; Chiara Milani; Daphne D'Amato; Sarah Elizabeth O'Donnell; Marco Carbone; Pietro Invernizzi
Journal:  Front Med (Lausanne)       Date:  2020-04-07

Review 2.  Fibrotic Events in the Progression of Cholestatic Liver Disease.

Authors:  Hanghang Wu; Chaobo Chen; Siham Ziani; Leonard J Nelson; Matías A Ávila; Yulia A Nevzorova; Francisco Javier Cubero
Journal:  Cells       Date:  2021-05-05       Impact factor: 6.600
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.